Glenmark Pharma Receives Us Fda Approval For Generic Tecfidera Dr Capsules
Glenmark Pharmaceuticals Has Been Granted Final Approval By The United States Food &Amp; Drug Administration (Fda) For Dimethyl Fumarate Delayed-Release Capsules, 120 Mg And 240 Mg, The Generic Version Of Tecfidera Delayed-Release Capsules, 120 Mg And 240 Mg, Of Biogen.According To Iqvia Sales Data For The 12 Month Period Ending August, The Tecfidera Delayed-Release Capsules, 120 Mg And 240 Mg Market Achieved Annual Sales Of Approximately $3.8 Billion.Glenmark&Rsquo;S Current Portfolio Consists Of 164 Products Authorised For Distribution In The Us Marketplace And 46 Anda&Rsquo;S Pending Approval With The Us Fda.In Addition To These Internal Filings, Glenmark Continues To Identify And Explore External Development Partnerships To Supplement And Accelerate The Growth Of Its Existing Pipeline And Portfolio.
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!